drugset
drugset / Trial / NCT03244657

Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy

NCT03244657 ↗

Phase 4 Unknown 200 enrolled Chengdu Kanghong Biotech Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To explore efficacy and safety of 0.5 mg conbercept ophthalmic injection for long-term treatment of polypoid choroidal vasculopathy (PCV) subjects.

Timeline

Start
2017-04-25
Primary completion
2019-10-31
Completion
2020-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Conbercept Protein / enzyme biologic 0.5 mg Intravitreal

Indications

No indication recorded.